ISIS-333611

The first ALS trial to block abnormal SOD1 protein using ‘antisense’ is set to open by the end of 2009

posted on October 19, 2009 - 9:00pm
A phase 1 clinical trial of the experimental drug ISIS-SOD1-Rx in patients with the SOD1-related type of familial (inherited) amyotrophic lateral sclerosis (ALS) is expected to begin before the end of 2009 at Washington University in St. Louis, Massachusetts General Hospital in Boston and four additional U.S. sites.

New content is being added every day. Please check back again.